Hugo Jourdain

Saint-denis-de-palin, 93285, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Overall survival according to COVID-19 mRNA vaccination co-exposure in patients treated with PD-(L)1 inhibitors: a French real-world cohort study.

Overall survival according to COVID-19 mRNA vaccination co-exposure in patients treated with PD-(L)1 inhibitors: a French real-world cohort study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 03, 2026

Trends and Characteristics of Opioid Use During Pregnancy Between 2010 and 2023: A French Nationwide Drug Utilization Study.

Trends and Characteristics of Opioid Use During Pregnancy Between 2010 and 2023: A French Nationwide Drug Utilization Study.

Journal: European journal of pain (London, England)

Published: January 12, 2026

Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer.

Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer.

Journal: British journal of cancer

Published: June 27, 2025

PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study.

PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study.

Journal: The Lancet regional health. Europe

Published: June 11, 2025

Use of the injectable contraceptive medroxyprogesterone acetate in France in 2010-2023: A national descriptive study.

Use of the injectable contraceptive medroxyprogesterone acetate in France in 2010-2023: A national descriptive study.

Journal: Therapie

Published: June 02, 2025

Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies.

Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies.

Journal: The Lancet regional health. Europe

Published: April 29, 2025

Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study.

Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: December 10, 2024

Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study.

Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study.

Journal: ESMO open

Published: September 25, 2024

Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study.

Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study.

Journal: The British journal of dermatology

Published: September 24, 2024

Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System.

Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System.

Journal: World journal of pediatrics : WJP

Published: September 04, 2024

Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study.

Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study.

Journal: Clinical and translational gastroenterology

Published: July 08, 2024

Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System.

Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System.

Journal: ESMO real world data and digital oncology

Published: June 03, 2024

Showing 1-12 of 19

Last Updated: 09/26/2026